How we engage with the public

Public policy areas

Roche is dedicated to fostering collaboration to align policies with the goal of improving patient care and healthcare innovation. By engaging with policymakers, Roche uses its global expertise as a healthcare pioneer to inform health policies that support sustainable systems and ensure patient access to treatments. Our evidence-based advocacy underscores our commitment to global health, addressing key issues like securing investment to ensure access to medicines, providing patients more convenient and efficient treatment models, and planning for future-proofed health innovation strategies.

Reform the medicines access and reimbursement landscape

Roche is dedicated to fostering collaboration to align policies with the goal of improving patient care and healthcare innovation. By engaging with policymakers, Roche uses its global expertise as a healthcare pioneer to inform health policies that support sustainable systems and ensure patient access to treatments. Our evidence-based advocacy underscores our commitment to global health, addressing key issues like securing investment to ensure access to medicines, providing patients more convenient and efficient treatment models, and planning for future-proofed health innovation strategies.

Increase the availability of innovative treatment models to relieve system capacity and give patients more choice

We are proud of Roche’s contributions to medical innovations that transform disease treatment. However, these medicines are only meaningful if accessible to those in need. It is our responsibility to ensure access to our treatments.

Improved treatment delivery models are essential for effective and efficient patient care. Roche believes innovative methods, like, can relieve health system capacity and offer patients shorter, more convenient administration.

Partner with the government to develop future proofed health innovation strategies and frameworks

Detecting signs of illness and diagnosing disease as early as possible is crucial if we’re to improve health outcomes for New Zealanders. In New Zealand, we react to a diagnosis rather than plan for it - to do that requires a systems-change level of thinking. We want to partner with the government to ensure that affordable, sustainable, accurate, and early diagnosis is available for all New Zealanders.

Our positions

●(31 July 2024)

●(23 March 2023; jointly submitted with Roche Diagnostics New Zealand)

●(3 March 2023; jointly submitted with Roche Diagnostics New Zealand)

Media releases

You can find our media releases.

Status of our medicines in New Zealand

You can find the current Pharmac funding status of our medicines on.

Corporate engagement

We work closely with a range of corporate organisations to develop meaningful relationships across the healthcare industry and business. We are proud to be members of:

●

●

●

●

●

● Aotearoa Genomic Health Alliance

Transparency disclosures

In line with the Roche Code of Conduct and the Medicines New Zealand Guidelines Disclosure of Transfer of Value, Roche Products (New Zealand) Ltd strongly supports openness and transparency on the transfers of value made to healthcare professionals, with the aim of increasing trust and confidence in the pharmaceutical industry. The aim of any support is to enhance medical knowledge, evolve the healthcare ecosystem and improve the quality use of medicines in New Zealand, ultimately benefiting patient care. The following report summarises the support (direct and indirect) provided by Roche to New Zealand healthcare professionals in 2023.

●